Loading organizations...
§ Private Profile · 10 Fitzroy Sq, London, Greater London, W1T 5HP, United Kingdom
Neu Health is a technology company.
I am unable to fetch the full page content for Neu Health (neu.health) due to a "429 Too Many Requests" error when trying to access the website. As the instructions require thorough research based on fetched full-page content, I cannot generate the company profile at this time.
Neu Health has raised $9.6M across 3 funding rounds.
Neu Health has raised $9.6M in total across 3 funding rounds.
Neu Health has raised $9.6M in total across 3 funding rounds.
Neu Health's investors include Nirdesh Gupta, Joel Schoppig, G. K. Goh, JIMCO, Social Impact Enterprises, SXSW London, Jim Laur, Heather Roxborough, Cedars-Sinai, Oxford Science Enterprises, Future Planet Capital, Optum Ventures.
Neu Health has raised $9.6M across 3 funding rounds. Most recently, it raised $5.6M Seed in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 9, 2025 | $5.6M Seed | Nirdesh Gupta, Joel Schoppig | G. K. GOH, JIMCO, Social Impact Enterprises, SXSW London | Announced |
| Jan 30, 2025 | $2M Venture Round | JIM Laur, Heather Roxborough | — | Announced |
| Jan 1, 2025 | $2M Seed | Cedars Sinai, Oxford Science Enterprises | Future Planet Capital, Optum Ventures | Announced |
Neu Health is a London-based HealthTech startup that builds a smartphone-based digital platform for neurology care, focusing on Parkinson's disease and dementia. It serves clinicians, caregivers, and patients by enabling remote monitoring of disease progression through a patient app requiring just 7 minutes of daily input, AI-driven analytics to predict clinical outcomes up to 18 months in advance, and clinician dashboards for optimized management, medication adjustments, and personalized therapies.[1][3] This solves the growing global challenge of neurodegenerative conditions—projected to affect 200 million people by 2050—by making advanced care accessible, reducing clinician burden, supporting independent living, and accelerating breakthroughs through data insights.[1][3]
The company demonstrates strong growth momentum, raising €1.9 million in 2025 from Oxford Science Enterprises and Cedars-Sinai, following participation in Cedars-Sinai's accelerator program. It's now piloting with 150 patients at Cedars-Sinai for US market entry, building on over 10 years of Oxford-validated research in 1,500+ participants.[3]
Neu Health was founded in 2022 as a University of Oxford spinout by CEO Caroline Cake and Dr. Kinan Muhammed, leveraging a decade of research by neurologists, neuroscientists, and data scientists.[1][3] The idea emerged from clinically validated trials involving over 1,500 participants, published in peer-reviewed journals, addressing the rising burden of Parkinson's and dementia through smartphone-accessible digital measures of symptoms like motor function, cognition, and mental health.[1][3]
Early traction came via Cedars-Sinai's 10th Accelerator program, paving the way for the recent €1.9 million funding and a six-month US pilot with 150 patients, marking its shift from UK-focused development to global expansion.[3]
Neu Health rides the wave of AI in neurodegenerative care, where rising prevalence—Parkinson's and dementia as top global causes by 2050—meets smartphone ubiquity and demand for value-based, remote health solutions.[1] Timing aligns with post-pandemic telehealth acceleration and US/UK investments in personalized medicine, amplified by aging populations and clinician shortages.[3]
Market forces like AI advancements in biomarker detection and payer shifts toward outcome-based models favor it, as seen in Cedars-Sinai partnerships.[3] Neu Health influences the ecosystem by validating digital neurology platforms, potentially standardizing remote monitoring and inspiring spinouts in other chronic diseases.
Neu Health is poised for US scale post-pilot, with funding fueling platform refinements and clinician adoption amid €1.9 million momentum.[3] Trends like AI predictive health, multimodal data integration, and global neurology crises will propel it, evolving from monitoring tool to full ecosystem player integrating wearables and genomics. Its Oxford roots and partnerships position it to redefine accessible neurocare, tying back to transforming smartphones into life-extending platforms for millions.